News

See you at MEDICA 2024: Accelerating diagnostic innovation

Agarose Bead Technologies will be exhibiting in Hall 3, Booth D95 from November 11-14 in Düsseldorf, Germany.

Read more

Next stop: The industry's top trade shows

Agarose Bead Technologies (ABT) is excited to announce our participation in several important trade fairs this October.

Read more

Agarose Bead Technologies expands facility to meet rising global demand for novel therapies market

Agarose Bead Technologies has enhanced its Burgos facility by boosting its agarose resin production to 100,000 liters annually to position itself as a powerhouse in the novel therapies market.

Read more

See you at Bioprocess International Conference and Exhibition 2024

ABT will be exhibiting at one of the most prestigious events in the bioprocessing industry, the Bioprocess International Conference. This prestigious event will be held...

Read more

The significance of protein purification in the fight against cancer

Discover how ABT's Nickel NTA Agarose Resin is paving the way for new immunotherapy breakthroughs that could transform treatments for immune-related diseases...

Read more

We’re celebrating: Our brand-NEW Website is live!

Our new website is more than just a visual upgrade. It represents our commitment to providing the best possible resources and information to our clients and partners in the bioprocessing and biopharmaceutical industries...

Read more

Unveiling the role of TAOK3 and SHP-1 in T cell activation: Protein isolation and purification

Modulation of SHP-1 abundance by TAOK3 serves as a rheostat for TCR signaling and determines the activation threshold of T lymphocytes.

Read more

Purifying HIV proteins to discover new therapeutic targets

ABT Antibody Purification Chromatography Resins have demonstrated that the instability of the HIV HLA-E peptidome may be a significant barrier...

Read more

Advancing bacteriophage research with Nickel NTA agarose resins

Our technology offers a unique advantage in studying bacteriophages, particularly in the purification and analysis of phage components like...

Read more

"ABT Antibody Purification resins have demonstrated that the instability of the HIV HLA-E peptidome may be a significant barrier to therapeutic targeting of these antigens"

Naturally occurring T cells may play a crucial role in universal immunotherapy by recognizing antigens through nonpolymorphic human leukocyte class Ib (HLA-E).

However, uncertainties remain regarding the biological relevance of these ligands due to poorly understood mechanisms of pathogen-derived peptide access to the HLA-E pathway.

Therefore, studying these HLA-E ligands is essential for addressing diseases as significant as HIV (1,2).

In this paper, among other informatic and cellular assays, researchers proceed with an immunopurification of peptide-HLA complexes from HIV infected cells using high-performance Agarose Bead Technologies (ABT) resins (Fig 1).

The ABT resins used were Protein L Agarose Resin linked to 3D12 antibody and Protein A Agarose Resin.

Figure 1. Schematic representation of performed cellular and biochemical assays followed by immunopurification (Adapted from 1).

The study highlights the potential contribution of ABT resins in pharmacological research and treatments.

ABT Antibody Purification Chromatography Resins have demonstrated that the instability of the HIV HLA-E peptidome may be a significant barrier to therapeutic targeting of these antigens.

Therefore, this instability must be considered a major challenge for drug development (3).

Further investigations should focus on achieving stable peptide HLA-E presentation to ensure consistent on-target immunotherapeutics.

  1. Wallace et al.,Instability of the HLA-E peptidome of HIV presents a major barrier to therapeutic targeting, Molecular Therapy (2024).
  2. Strong, R.K., Holmes, M.A., Li, P., Braun, L., Lee, N., and Geraghty, D.E. (2003). HLA-E Allelic Variants correlating differential expression, peptide affinities, crystal structures, and thermal stabilities. J. Biol. Chem. 278, 5082–5090.
  3. Sauter, J., Putke, K., Schefzyk, D., Pruschke, J., Solloch, U.V., Bernas, S.N., Massalski, C., Daniel, K., Klussmeier, A., Hofmann, J.A., et al. (2021). HLA-E typing of more than 2.5 million potential hematopoietic stem cell donors: Methods and population-specific allele frequencies. Hum. Immunol. 82, 541–547.
Cookie consent
Product added to wishlist